Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Gains from Investment Securities (2021 - 2023)

Werewolf Therapeutics (HOWL) has disclosed Gains from Investment Securities for 3 consecutive years, with $136000.0 as the latest value for Q4 2023.

  • Quarterly Gains from Investment Securities rose 111.23% to $136000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was -$1.3 million through Sep 2023, down 109.06% year-over-year, with the annual reading at -$7000.0 for FY2022, 100.05% down from the prior year.
  • Gains from Investment Securities for Q4 2023 was $136000.0 at Werewolf Therapeutics, up from -$136000.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was $13.7 million in Q4 2021, with the low at -$1.2 million in Q4 2022.
  • Average Gains from Investment Securities over 3 years is $1.7 million, with a median of $8000.0 recorded in 2022.
  • Peak annual rise in Gains from Investment Securities hit 111.23% in 2023, while the deepest fall reached 6700.0% in 2023.
  • Over 3 years, Gains from Investment Securities stood at $13.7 million in 2021, then tumbled by 108.87% to -$1.2 million in 2022, then surged by 111.23% to $136000.0 in 2023.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at $136000.0, -$136000.0, and -$18000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.